Funding for this research was provided by:
Strategic Research Council (303430)
Business Finland (2726/31/2014)
Academy of Finland (286028)
Received: 13 December 2020
Accepted: 8 June 2021
First Online: 28 June 2021
: The ethics committee of the Central Finland Health Care District has approved the Elixir study (reference number 7 U/2012). All participants gave written informed consent before taking part in this study.
: Not applicable.
: T.M. is currently an employee and stockowner of Firstbeat Technologies Ltd., Jyväskylä, Finland. At the time that the Elixir intervention study was designed and conducted, he worked at the University of Jyväskylä. He did not participate in data analysis or writing the conclusions. No other conflicts of interest are declared by the authors.